Paul Castellani

Marseille, 13000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in Prognosis.

Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in Prognosis.

Journal: Biomedicines

Published: March 01, 2026

Nonsurgical hepatocellular carcinoma treated with selective internal radiation therapy and personalized dosimetry: real-life data from French centers.

Nonsurgical hepatocellular carcinoma treated with selective internal radiation therapy and personalized dosimetry: real-life data from French centers.

Journal: Chinese clinical oncology

Published: June 30, 2025

Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.

Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study.

Journal: Journal of viral hepatitis

Published: October 14, 2024

Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study.

Outcomes and safety of atezolizumab plus bevacizumab in the treatment of hepatocellular carcinoma: treatment prognosis and comparison with tyrosine kinase inhibitors in a French multicenter matched real-life study.

Journal: European journal of gastroenterology & hepatology

Published: July 31, 2024

Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis.

Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis.

Journal: Journal of clinical and translational hepatology

Published: December 02, 2022

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.

Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching.

Journal: World journal of gastrointestinal oncology

Published: March 21, 2022

Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

Journal: World journal of clinical cases

Published: November 07, 2020

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Journal: European journal of gastroenterology & hepatology

Published: May 03, 2019

Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.

Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis.

Journal: Liver cancer

Published: August 08, 2018

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?

Journal: Therapeutic advances in gastroenterology

Published: May 16, 2018

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.

Journal: European journal of gastroenterology & hepatology

Published: February 01, 2018

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.

Journal: Translational gastroenterology and hepatology

Published: November 22, 2017

Showing 1-12 of 27

Last Updated: 09/26/2026